Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG ALL-B12 study in newly diagnosed pediatric B-cell precursor acute lymphoblastic leukemia
jRCTs041180101Phase 3Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, dexamethasone, prednisolone, asparaginase escherichia coli and methotrexate in acute lymphoblastic leukemia (ALL) (6 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Five-year event-free survival by risk group. Started Nov 2012; status: completed.
02
Drugs
vincristinedexamethasoneprednisoloneasparaginase escherichia colimethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041180101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180101.